Understanding GLP-1: Benefits And Uses For Diabetes And Weight Loss

Glucagon-like peptide-1 (GLP-1) has emerged as a promising treatment option for individuals with type 2 diabetes and those struggling with weight loss. GLP-1 agonists, a class of diabetes medication, have gained significant attention due to their ability to effectively manage blood sugar levels while promoting appetite suppression and weight reduction. Understanding the mechanism of action, benefits, and potential side effects of GLP-1 is crucial for both healthcare professionals and patients considering this therapeutic approach.

This article delves into the world of GLP-1, exploring its role in the body and its applications in the management of type 2 diabetes and obesity. We will discuss the different types of GLP-1 drugs available, including the well-known semaglutide, and compare them to other diabetes medications like DPP-4 inhibitors. Furthermore, we will address potential side effects such as nausea, vomiting, diarrhea, and rare cases of pancreatitis and thyroid cancer. By the end of this article, readers will have a comprehensive understanding of GLP-1 and its implications for diabetes and weight management.

What is GLP-1?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by the small intestine that plays a crucial role in regulating blood sugar levels and appetite. GLP-1 belongs to the glucagon peptide superfamily and is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

GLP-1 has several functions in the body, including:

Triggering insulin release from the pancreas in response to high blood sugar levels
Blocking the secretion of glucagon, a hormone that raises blood sugar levels
Slowing stomach emptying, which prevents significant spikes in postprandial blood glucose
Increasing feelings of fullness (satiety) after eating by affecting areas of the brain that process hunger and satiety

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic the effects of the naturally occurring GLP-1 hormone. These medications are primarily used to manage blood sugar levels in individuals with type 2 diabetes and can also help with weight loss in obese individuals. GLP-1 RAs are typically administered as injectable medications, with the liquid medication injected into the fatty tissue just under the skin (subcutaneous injection).

The secretion of GLP-1 from the gut appears to be impaired in obese individuals, suggesting a potential role in the pathophysiology of obesity. The combined central and peripheral actions of GLP-1 RAs promote satiety, decrease hunger, and ultimately reduce food intake, leading to weight loss. While GLP-1 RA-induced deceleration of gastric emptying and occasional nausea may contribute to the weight-reducing effects, they appear to play a minor and temporary role.

The inhibition of food intake by GLP-1 RAs has been attributed to both direct central actions, with GLP-1 receptors present in brain regions involved in food intake and energy balance, and indirect pathways via vagal afferents originating in the gut and portal circulation.

Mechanism of Action

GLP-1 agonists work by mimicking the naturally occurring hormone glucagon-like peptide-1 (GLP-1) produced in the small intestine. When blood sugar levels start to rise after eating, these drugs stimulate the body to produce more insulin, helping to lower blood sugar levels. GLP-1 agonists also block the secretion of glucagon, a hormone that raises blood sugar levels, and slow stomach emptying, preventing significant spikes in postprandial blood glucose.

In addition to their effects on blood sugar control, GLP-1 agonists increase feelings of fullness (satiety) after eating by affecting areas of the brain that process hunger and satiety. The combined central and peripheral actions of GLP-1 agonists promote satiety, decrease hunger, and ultimately reduce food intake, leading to weight loss.

The inhibition of food intake by GLP-1 agonists has been attributed to both direct central actions, with GLP-1 receptors present in brain regions involved in food intake and energy balance, and indirect pathways via vagal afferents originating in the gut and portal circulation.

Recent research has focused on understanding the exact mechanisms by which GLP-1 agonists contribute to reduced calorie consumption. A review of existing medical literature found that:

The weight loss in the early stages of using GLP-1 agonists is not linked to nausea, a common side effect.
While the impact of the drug on reducing eating drops between 12-18 months, users’ caloric intake remains more restricted than baseline during the maintenance phase.
Studies have shown an overall lower desire for dairy, starchy, salty, and spicy foods, as well as a reduced desire for high-fat, non-sweet foods.
Macronutrient profiles of what people eat remain the same before and after initiation of the drug.
Semaglutide, a GLP-1 agonist, does not permeate the blood-brain barrier but instead interrupts signaling that could affect appetite in parts of the central nervous system not behind the blood-brain barrier.

These findings provide valuable insights into the complex mechanisms by which GLP-1 agonists like semaglutide and liraglutide promote weight loss and improve blood sugar control in individuals with type 2 diabetes and obesity.

Uses of GLP-1 Agonists

GLP-1 agonists are a class of medications primarily used to treat type 2 diabetes mellitus (T2DM) and promote weight loss in obese individuals. These drugs mimic the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1), which stimulates the body to produce more insulin when blood sugar levels start to rise after eating. GLP-1 agonists also block the secretion of glucagon, a hormone that raises blood sugar levels, and slow stomach emptying, preventing significant spikes in postprandial blood glucose.

Type 2 Diabetes

The American Diabetes Association (ADA) recommends considering the addition of a GLP-1 agonist in patients with a contraindication or intolerance to metformin, those with a hemoglobin A1c greater than 1.5% over target, or those who do not reach their target A1c within 3 months, particularly in patients with atherosclerosis, heart failure, or chronic kidney disease. Semaglutide and high-dose liraglutide are FDA-approved as pharmacologic treatments for obesity or can be prescribed to overweight patients with comorbidities.

According to the 2023 ADA guidelines, GLP-1 receptor agonists are recommended for mitigating cardiovascular risk. These agents not only lower the chances of cardiovascular events and hypoglycemia but also demonstrate potential in potentially decreasing the progression of chronic kidney disease (CKD). GLP-1 agonists with proven cardiovascular benefits include liraglutide, subcutaneous semaglutide, and dulaglutide.

Obesity and Weight Loss

The FDA currently approves the use of semaglutide and high-dose liraglutide to help treat obesity, defined as a body mass index (BMI) of 30 or higher. Healthcare providers may also prescribe semaglutide or high-dose liraglutide for people who have overweight (BMI of 25 to 29.9) along with other health conditions if losing weight can help manage the coexisting conditions.

Obesity is a complex condition, and effective management often requires several therapies, including dietary changes, exercise, medications, behavior modification programs, and bariatric (weight loss) surgery. If you have obesity or overweight, talk to your healthcare provider to see if a GLP-1 agonist is right for you.

Types of GLP-1 Drugs

There are several GLP-1 receptor agonist medications currently available, which can be categorized into injectable and oral formulations.

Injectable GLP-1 Drugs

The injectable GLP-1 receptor agonists include:

Dulaglutide (Trulicity) – administered once weekly
Exenatide (Byetta) – administered twice daily
Exenatide extended-release (Bydureon) – administered once weekly
Liraglutide (Victoza) – administered once daily
Lixisenatide (Adlyxin) – administered once daily
Semaglutide injection (Ozempic) – administered once weekly

These injectable medications mimic the effects of the naturally occurring GLP-1 hormone, helping to lower blood sugar levels and promote weight loss. They work by stimulating insulin secretion, inhibiting glucagon release, slowing stomach emptying, and increasing feelings of fullness.

The most common side effects associated with injectable GLP-1 receptor agonists include nausea and vomiting, which tend to be more prevalent when starting or increasing the dose. Injection site reactions, such as pain, redness, and skin lumps, may also occur.

Oral GLP-1 Drugs

Semaglutide is currently the only GLP-1 receptor agonist available in an oral formulation, sold under the brand name Rybelsus. This medication is taken once daily and has been shown to be effective in lowering blood sugar levels and promoting weight loss in individuals with type 2 diabetes.

Oral semaglutide undergoes a unique absorption process, allowing it to reach the target tissues more easily despite being a peptide medication. This innovative formulation provides a convenient alternative to injectable GLP-1 receptor agonists, as it eliminates the need for needles and may improve treatment adherence.

The most common side effects of oral semaglutide are similar to those of injectable GLP-1 receptor agonists, including nausea, vomiting, and diarrhea. However, oral semaglutide may interact with other oral medications taken on the same schedule, potentially affecting their absorption.

Both injectable and oral GLP-1 receptor agonists have been shown to be effective in managing type 2 diabetes and promoting weight loss. The choice between these formulations depends on individual preferences, lifestyle factors, and potential drug interactions, and should be made in consultation with a healthcare provider.

Side Effects of GLP-1 Agonists

The most common side effects associated with GLP-1 receptor agonists include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and loss of appetite. These side effects are more likely to occur when starting the medication or increasing the dose. Nausea appears to be less common with long-acting GLP-1 agonists compared to short-acting compounds.

Other common side effects of GLP-1 receptor agonists include:

Dizziness
Mild tachycardia (increased heart rate)
Infections
Headaches
Indigestion (upset stomach)

Injection site reactions, such as rash, erythema, or itching at the injection site, are also common with GLP-1 receptor agonists. These reactions are reported more frequently with long-acting than short-acting GLP-1 receptor agonists. The predominant injection site reaction is pruritus, which is usually transient and does not cause discontinuation of treatment.

Serious Side Effects

Severe but rare side effects of GLP-1 receptor agonists can include:

Pancreatitis
Medullary thyroid cancer
Acute kidney injury
Worsening diabetes-related retinopathy

Concerns have been raised regarding a possible association between GLP-1 receptor agonist treatment and pancreatic inflammation and pancreatitis. However, several recent studies and meta-analyses have failed to show an increased risk of pancreatitis with the use of GLP-1 receptor agonists.

GLP-1 receptor agonists have been associated with the development of acute kidney injury in some case reports, primarily through hemodynamic derangement due to nausea, vomiting, and diarrhea. Exenatide has been linked to acute kidney injury in about 100 case reports, while liraglutide has been associated with acute kidney injury in a few case reports.

Severe anaphylactic reactions with GLP-1 receptor agonists have not been reported in PubMed. However, post-marketing reports show that anaphylactic reactions occur rarely with liraglutide, very rarely with exenatide, and uncommonly with lixisenatide.

Benefits Beyond Blood Sugar Control

GLP-1 receptor agonists offer a range of benefits that extend beyond their primary role in managing blood sugar levels. These medications have demonstrated significant cardiovascular benefits and additional health advantages, making them a valuable therapeutic option for individuals with type 2 diabetes and obesity.

Cardiovascular Benefits

GLP-1 receptor agonists have shown promising results in reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes. Several cardiovascular outcome trials (CVOTs) have consistently demonstrated that GLP-1 receptor agonists can lower the chances of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.

These medications exert their cardioprotective effects through various mechanisms. They promote weight loss, reduce blood pressure, improve lipid profiles, and have anti-inflammatory and antiatherogenic properties. By targeting multiple cardiovascular risk factors, GLP-1 receptor agonists contribute to improved cardiovascular health in individuals with type 2 diabetes.

Moreover, GLP-1 receptor agonists have shown potential in reducing the progression of chronic kidney disease in patients with type 2 diabetes compared to placebo. This renal protective effect further highlights the comprehensive cardiovascular benefits of these medications.

Additional Health Benefits

In addition to their cardiovascular advantages, GLP-1 receptor agonists offer a range of other health benefits. These medications effectively promote weight loss by increasing feelings of fullness, reducing appetite, and slowing gastric emptying. Weight reduction is a crucial aspect of managing type 2 diabetes and obesity, as it can improve insulin sensitivity and overall metabolic health.

GLP-1 receptor agonists have also been associated with improvements in lipid profiles. Studies have shown modest reductions in LDL cholesterol, total cholesterol, and triglycerides in patients treated with these medications compared to controls. By positively influencing lipid levels, GLP-1 receptor agonists contribute to a reduced risk of cardiovascular complications.

Furthermore, GLP-1 receptor agonists have demonstrated anti-inflammatory effects. Compared to other antidiabetic treatments, these medications have significantly reduced inflammatory biomarkers. The anti-inflammatory properties of GLP-1 receptor agonists may play a role in reducing the formation and progression of atherosclerotic lesions.

The multifaceted benefits of GLP-1 receptor agonists, encompassing cardiovascular protection, weight management, lipid profile improvements, and anti-inflammatory effects, make them a valuable tool in the comprehensive management of type 2 diabetes and obesity. As research continues to unravel the full potential of these medications, healthcare providers can leverage their diverse benefits to optimize patient outcomes and reduce the burden of diabetes-related complications.

New Developments in GLP-1 Research

The field of GLP-1 research is rapidly evolving, with several new drugs and ongoing clinical trials showing promising results for the treatment of obesity and type 2 diabetes. The FDA recently approved Zepbound (tirzepatide), a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Tirzepatide has demonstrated significant weight loss and improvements in cardiometabolic risk factors in clinical trials.

Pfizer is advancing the development of danuglipron, an oral GLP-1 receptor agonist candidate, with an ongoing phase 2b study in obesity that is fully enrolled. Danuglipron represents the largest oral, small molecule GLP-1 receptor agonist clinical development program underway, with over 1,400 participants enrolled for the treatment of obesity and type 2 diabetes. However, Pfizer has decided to discontinue the development of another GLP-1 receptor agonist candidate, lotiglipron, based on pharmacokinetic data and elevated transaminases observed in clinical studies.

Emerging GLP-1 Drugs

Several pharmaceutical companies are developing new GLP-1 drugs to address the growing demand for effective obesity and diabetes treatments. Eli Lilly and Novo Nordisk are leading the race, with their respective drugs, tirzepatide (Mounjaro) and semaglutide (Ozempic and Wegovy), showing remarkable weight loss results in clinical trials. Some of the experimental drugs in development may go beyond diabetes and weight loss, improving liver and heart function while reducing side effects such as muscle loss common to the existing medications.

At the 2024 American Diabetes Association conference, researchers are expected to present data on 27 GLP-1 drugs in development, ranging from early-stage preclinical to late-stage clinical trials. These new drugs aim to enhance and complement the efficacy and mechanisms of action of existing GLP-1 receptor agonists, potentially leading to even greater weight loss and cardiometabolic benefits.

Ongoing Clinical Trials

Numerous clinical trials are currently underway to assess the safety and efficacy of novel GLP-1 receptor agonists and combination therapies. Oral semaglutide, developed by Novo Nordisk, has shown promising results in the OASIS-1 trial, with participants achieving 17.4% weight loss compared to 1.8% with placebo. The PIONEER PLUS trial demonstrated that oral semaglutide 50 mg led to 9.8% weight loss and a 2.1% reduction in HbA1c in people with type 2 diabetes.

Orforglipron, a once-daily, oral, non-peptide GLP-1 receptor agonist, has shown dose-dependent weight loss of up to 14.7% in people with obesity and a 2.1% reduction in HbA1c in people with type 2 diabetes in phase 2 trials. Multiple phase 3 trials with oral semaglutide and orforglipron are ongoing, while another oral GLP-1 receptor agonist, CT-996, is in early phase clinical trials.

Other notable ongoing clinical trials include:

Retatrutide (LY3437943), a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown up to 24.2% weight loss in a phase 2 study and is currently in phase 3 trials (TRIUMPH program).
Cagrisema (cagrilintide + semaglutide), a combination of a long-acting amylin analogue and a GLP-1 receptor agonist, has demonstrated up to 17.1% weight loss in a phase 1b trial and is undergoing phase 3 trials (REDEFINE program).
Mazdutide (IBI362 or LY3305677), a once-weekly oxyntomodulin analogue acting on both GLP-1 and glucagon receptors, has shown up to 11.3% weight loss in a phase 2 trial and is progressing to phase 3 studies.

These ongoing clinical trials highlight the rapid advancements in GLP-1 research and the potential for new, more effective therapies for obesity and type 2 diabetes in the near future. As more data becomes available, healthcare professionals will have a broader range of options to personalize treatment plans and optimize patient outcomes.

Conclusion

The development of GLP-1 receptor agonists has revolutionized the management of type 2 diabetes and obesity, offering a multifaceted approach to improving metabolic health. By mimicking the effects of the naturally occurring GLP-1 hormone, these medications effectively lower blood sugar levels, promote weight loss, and provide cardiovascular benefits. As research continues to uncover the full potential of GLP-1 receptor agonists, healthcare providers can leverage their diverse benefits to optimize patient outcomes and reduce the burden of diabetes-related complications.

The future of GLP-1 research is bright, with numerous ongoing clinical trials and novel drugs in development. As more data becomes available, healthcare professionals will have a broader range of options to personalize treatment plans and address the growing demand for effective obesity and diabetes treatments. With the continued advancements in GLP-1 research, we can look forward to more targeted and efficient therapies that will help individuals with type 2 diabetes and obesity lead healthier, more fulfilling lives.

FAQs

1. How does GLP-1 contribute to weight loss?
GLP-1 medications help reduce appetite and slow down the digestion of food from the stomach to the small intestine. This can make you feel fuller sooner and for a longer duration, leading to decreased food intake.

2. What are the criteria for using GLP-1 medications for weight loss?
GLP-1 medications have been prescribed for diabetes management since 2005 and were approved by the FDA in 2014 for weight loss in individuals with a Body Mass Index (BMI) of 30 or higher, or a BMI of at least 27 with an associated weight-related health condition.

3. Which GLP-1 medication is most effective for managing diabetes?
Tirzepatide has shown the highest efficacy in improving glycaemic control by reducing HbA1c levels and fasting blood glucose. For weight management in type 2 diabetes, CagriSema has been noted as the most effective in facilitating weight loss.

4. What are the main benefits of using GLP-1 medications?
GLP-1 receptor agonists offer several benefits including enhancing weight loss, slowing gastric emptying, reducing both systolic and diastolic blood pressure, and decreasing total cholesterol levels.

Understanding GLP-1: Benefits and Uses for Diabetes and Weight Loss